OTCMKTS:JCRRF

JCR Pharmaceuticals - JCRRF Stock Forecast, Price & News

$10.40

0.00 (0.00%)

(As of 03/22/2023 12:00 AM ET)

Add

Compare

Today's Range: $10.40
▼
$10.40
50-Day Range: $10.40
▼
$19.24
52-Week Range: $10.40
▼
$12.38

Volume: N/A
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About JCR Pharmaceuticals (OTCMKTS:JCRRF) Stock

JCR Pharmaceuticals Co., Ltd., a specialty pharmaceuticals company, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company also develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells medical devices and laboratory instruments. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.

Receive JCRRF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for JCR Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

JCRRF Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

30 days | 90 days | 365 days | Advanced Chart

Receive JCRRF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for JCR Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Drug Manufacturers - General
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:JCRRF
CUSIP: N/A
CIK: N/A
Web: www.jcrpharm.co.jp
Phone: 81 7 9732 8591
Fax: N/A
Employees: 732
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

Key Executives

Mr. Shin Ashida (Age 80)
Chairman, CEO & Pres

Yoshihiro Ota
Director of Accounting Department & Corp. Strategy Department (Fin.)

Yutaka Honda
Sr. Corp. Officer,Exec. Director of Admin. Divs. & Director of Gen. Affairs Dept

Hiroyuki Fukuya
Director of Legal Affairs Department - Admin. Division

Toru Ashida (Age 55)
Sr. VP of Sales & Admin., Exec. Director of Sales Division and Director

Ryutaro Makino
Director of Marketing Dept. & Group Mang. of Product Planning - Marketing Dept. for Sales Div.

Yoshiaki Ijiri
Director of HR Planning Dept.

Katsuya Nishino (Age 67)
Exec. VP

Tatsuo Suzuki Ph.D. (Age 69)
MD, GM of Quality Assurance Division & Director of Regulatory Affairs

Hiroshi Yoshimoto (Age 72)
Sr. Advisor

Key Competitors

View All Competitors

JCRRF Stock - Frequently Asked Questions

Should I buy or sell JCR Pharmaceuticals stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for JCR Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" JCRRF shares.
View JCRRF analyst ratings or view top-rated stocks.
How have JCRRF shares performed in 2023?: JCR Pharmaceuticals' stock was trading at $19.24 at the beginning of 2023. Since then, JCRRF shares have decreased by 45.9% and is now trading at $10.40.
View the best growth stocks for 2023 here.
Are investors shorting JCR Pharmaceuticals?: JCR Pharmaceuticals saw a decline in short interest in February. As of February 15th, there was short interest totaling 286,300 shares, a decline of 10.4% from the January 31st total of 319,700 shares. Based on an average daily volume of 200 shares, the short-interest ratio is currently 1,431.5 days.
View JCR Pharmaceuticals' Short Interest.
What is JCR Pharmaceuticals' stock symbol?: JCR Pharmaceuticals trades on the OTCMKTS under the ticker symbol "JCRRF."

How do I buy shares of JCR Pharmaceuticals?: Shares of JCRRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is JCR Pharmaceuticals' stock price today?: One share of JCRRF stock can currently be purchased for approximately $10.40.
How many employees does JCR Pharmaceuticals have?: The company employs 732 workers across the globe.
How can I contact JCR Pharmaceuticals?: JCR Pharmaceuticals' mailing address is 3-19 Kasuga-cho, Ashiya, Hyogo 659-0021. The official website for the company is www.jcrpharm.co.jp. The company can be reached via phone at 81 7 9732 8591.

This page (OTCMKTS:JCRRF) was last updated on 3/23/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial